|
Cell Therapeutics Inc.
develops, acquires, and commercializes innovative treatments for cancer,
and is developing a diversified portfolio of oncology products focused
on identifying new, less toxic, and more effective cancer therapies.
Ception Therapeutics is an emerging biopharmaceutical company
focused on the discovery and development of novel products to address
unmet medical needs.
Chroma Therapeutics
is the first biotechnology company founded to exploit the potential of
chromatin biology for cancer drug discovery. Chroma is focused on the
identification of novel anti-cancer agents that combine the efficacy of
cytotoxics with the tumour cell selectivity of modern targeted
therapeutics.
Based in Oxford, UK, Chroma is
developing a pipeline of novel anti-cancer drugs, primarily by
exploiting the world-class expertise of its founders in
the field of chromatin biology and the development of new molecular
cancer therapeutics.
Confluent
is a private medical device company pioneering the development of
In-situ-polymerized Biomaterials. These materials have almost universal
applications across minimally invasive surgery because they allow the
safe, simple, and rapid formation of customized implants at the site of
disease. This process can take place rapidly when two aqueous solutions
of molecularly designed synthetic polymers mix together. Confluent's
vision is to address unmet needs in surgery and interventional
procedures using its technology platform of in situ polymerization.
Elusys Therapeutics, Inc.
is focused on the development of first-in-class antibody therapies for
the treatment of infectious disease. The company's most advanced
product, Anthim, is a therapeutic for the treatment of Anthrax, a
Category A biowarfare agent. In the commercial sector, Elusys is
applying its Heteropolymer technology in the development of
Staphylococcus aureus infections. The company intends to apply the
Heteropolymer technology to the development of similar antibody-based
therapies to treat other bacterial and viral infections.
Intercell AG, (formerly Iomai
Corp.) has developed a method to safely and
more effectively deliver vaccines through the use of a skin patch and
without any injections.
Founded in 1989,
La Jolla Pharmaceutical Company
is a biotechnology company leading the development and marketing
of novel therapeutics for antibody-mediated autoimmune diseases, such as
lupus and antibody-mediated thrombosis.
LifeCell Corporation
develops and markets biologic products for the repair or replacement of
damaged or inadequate tissues. The Company's core preservation
technology produces an acellular tissue matrix, which retains the
essential biochemical and structural components necessary for normal
tissue regeneration.
Light Sciences Oncology (LSO) has developed an innovative,
practical, targeted therapy that can destroy previously untreatable
tumors. Its therapeutic platform combines
the best-in-class light activated drug and novel light generation
devices to destroy tumors from the inside out. Phase
III clinical trials will soon start to treat patients with the two major
cancer killers in the world -- hepatoma and metastatic colorectal
cancer. Light Sciences Oncology intends to provide physicians with the
tools to treat cancer as a non-life threatening chronic disease.
Open Monoclocal Technologies
Open
Monoclocal Technologies
(OMT) is an early-stage biotech company based in Palo Alto,
California, intends to develop a novel monoclonal-antibody producing
platform that is based upon the generation of human monoclonal
antibodies in a proprietary transgenic rat. A new and
unencumbered antibody-producing platform is expected to be of considerable value in
the years to come.
Symphogen A/S
is an early-stage,
technology-platform company that is developing a method to produce
antigen-specific human polyclonal antibody preparations via
recombinant or cell culture manufacturing techniques. This would
provide a potentially unlimited supply of human polyclonal antibodies
against any desired target compound(s) or pathogen(s) – obviating the
need to purify immunologically-active, polyclonal antibodies from either
human blood or other non-human blood sources.
Targeted Genetics Corp.
is a leader in gene delivery technology and in the development of
therapeutic products based on gene delivery.
|
